頁籤選單縮合
題名 | Toujeo藥物使用評估=The Evaluation of Medical Waste for Toujeo |
---|---|
作者姓名(中文) | 賴怡珊; 童玟津; | 書刊名 | 藥學雜誌 |
卷期 | 33:4=133 2017.12[民106.12] |
頁次 | 頁125-129 |
分類號 | 418.271 |
關鍵詞 | 藥物浪費; Toujeo; Lantus; Insulin glargine; |
語文 | 中文(Chinese) |
中文摘要 | Toujeo 是食藥署於2016年新核准上市的長效型胰島素,與 Lantus 具有相同的成分 以及相當的療效,但其所提供的胰島素血中濃度較平緩,造成低血糖的風險也較低, 此外,劑型設計上具有較高的濃度,使患者在相同劑量下所需注射的體積較低,相對 來說注射時的不適感也較低。某中部地區醫院已於2016年10月開始陸續將使用 Lantus 的患者轉換成 Toujeo,但考量 Toujeo 單支所含的藥量較多,有造成藥物浪費的疑慮, 因而設計本研究來探討從 Lantus 轉換成 Toujeo 後,造成藥物浪費程度的差異,結果顯 示 Toujeo 確實較 Lantus 易造成藥物浪費,應教育患者主動於看診時呈報家中所剩的胰 島素筆型注射劑支數,讓醫師開立處方時扣除家中剩餘藥量,以增進醫療資源的正確 利用,減少醫療浪費。 |
英文摘要 | Toujeo, the new long-acting insulin for adults with diabetes, was approved by the Taiwan Food and Drug Administration in 2016. Toujeo has the same active ingredient as Lantus and achieved comparable glycaemic control to that seen with Lantus. Toujeo has a more stable pharmacokinetic profile than Lantus so the risk of hypoglycemia was lower. Moreover, it is three times more concentrated so the injection volume was smaller, which may make patients feel more comfortable. Lots of hospitals had changed from Lantus to Toujeo. However, we concerned that will waste medical resources because of the higher dosage of each Toujeo. Our study evaluated the difference in medical waste between Lantus and Toujeo. The results showed the use of Toujeo make patients had more remaining medicine. We should educate patients to talk to their doctor about how much remaining medicine they have, and then the doctor can deduct the remaining medicine on the prescription. By doing so, we can decrease the waste of the medical resource. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。